• Immunic named Erik Lundgren chief executive officer, effective May 22, 2026; employment begins June 1.
• Lundgren was most recently senior vice president, Commercial Portfolio Organization at Genentech; previously general manager of Roche Czech Republic.
• He succeeds Daniel Vitt, who will retain responsibility for scientific strategy and portfolio advancement, remaining on the board.
• Management change comes as the company advances vidofludimus calcium in the phase 3 ENSURE program in relapsing multiple sclerosis.
• Immunic is also preparing a planned phase 3 program in primary progressive multiple sclerosis, alongside NDA and commercialization preparations.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Immunic Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202605270630PR_NEWS_USPR_____NY67899) on May 27, 2026, and is solely responsible for the information contained therein.